Claudia Calderón
Claudia Calderón has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Clara Inés Agudelo
Grupo de Microbiología, Instituto Nacional de Salud, Bogota 111321, Colombia
1 shared publication - Diego Rosselli
Pontificia Universidad Javeriana, Bogotá, Colombia
1 shared publication - Eduardo Ortega-Barria
B GSK , Panama city , Panama
1 shared publication - Elizabeth Castañeda
Grupo de Microbiología, Instituto Nacional de Salud, Bogota 111321, Colombia
1 shared publication - Rodrigo DeAntonio
Department of Population Intelligence, Endpoints Research Sites Network, Panama, Panama, Panama
1 shared publication - Romulo E Colindres
GlaxoSmithKline Biologicals, Wavre, Belgium
1 shared publication
Latest Publications
- Open Access
- 28 May 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 124
Streptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990–2010
Pneumococcal conjugate vaccines (PCVs) are in the process of implementation in Latin America. Experience in developed countries has shown that they reduce the incidence of invasive and non-invasive disease. However, there is evidence that the introduction of PCVs in universal mass vaccination programs, combined with inappropriate and extensive use of antibiotics, could be associated to changes in non-PCV serotypes, including serotype 19A. We conducted a systematic review to determine the distribution of serotype 19A, burden of pneumococcal disease and antibiotic resistance in the region.
- 28 May 2012
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 12 (1) , 124
Open AccessStreptococcus pneumoniae serotype 19A in Latin America and the Caribbean: a systematic review and meta-analysis, 1990–2010
Pneumococcal conjugate vaccines (PCVs) are in the process of implementation in Latin America. Experience in developed countries has shown that they reduce the incidence of invasive and non-invasive disease. However, there is evidence that the introduction of PCVs in universal mass vaccination programs, combined with inappropriate and extensive use of antibiotics, could be associated to changes in non-PCV serotypes, including serotype 19A. We conducted a systematic review to determine the distribution of serotype 19A, burden of pneumococcal disease and antibiotic resistance in the region.